ARL8A

Across TCGA pan-cancer cohorts, ARL8A Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated ARL8A data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher ARL8A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ARL8A expression acts as an unfavorable survival marker.

CHOL are the cancer types where ARL8A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	OS	Median	All	0.155	0.725	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

ARL8A–CHOL (OS)

Open the CHOL breakdown →